These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 18477967

  • 1. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
    Lichtenstein GR, Rubin DT, Sabesin SM, Velayos FS, Vitat P.
    Rev Gastroenterol Disord; 2008; 8(1):21-30; quiz 31-2. PubMed ID: 18477967
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
    Kane SV, Cohen RD, Aikens JE, Hanauer SB.
    Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328
    [Abstract] [Full Text] [Related]

  • 3. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L, Wilson L.
    Gastroenterol Nurs; 2007 Oct; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [Abstract] [Full Text] [Related]

  • 4. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.
    Tindall WN, Boltri JM, Wilhelm SM.
    J Manag Care Pharm; 2007 Sep; 13(7 Suppl A):S2-12; quiz S13-4. PubMed ID: 17874873
    [Abstract] [Full Text] [Related]

  • 5. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 6. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Nov; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 7. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.
    Bernick SJ, Kane S.
    Expert Rev Clin Immunol; 2010 Jul; 6(4):677-82. PubMed ID: 20594140
    [Abstract] [Full Text] [Related]

  • 8. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B.
    Tidsskr Nor Laegeforen; 2003 Sep 25; 123(18):2565-7. PubMed ID: 14714043
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S, Kamm MA, Lichtenstein GR.
    Expert Rev Gastroenterol Hepatol; 2008 Jun 25; 2(3):299-314. PubMed ID: 19072380
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R.
    Clin Gastroenterol Hepatol; 2003 Jan 25; 1(1):36-43. PubMed ID: 15017515
    [Abstract] [Full Text] [Related]

  • 14. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec 25; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
    Kao J, Kwok K, Das KM.
    J Clin Gastroenterol; 2010 Sep 25; 44(8):531-5. PubMed ID: 20495466
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T, Probert CS, Keshav S.
    Aliment Pharmacol Ther; 2006 Sep 25; 24 Suppl 1():17-22. PubMed ID: 16939425
    [Abstract] [Full Text] [Related]

  • 20. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC, Hanauer SB.
    Rev Gastroenterol Disord; 2004 Sep 25; 4(3):104-17. PubMed ID: 15359211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.